|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Revisiting the Role of Computerized Tomographic Scan and Cystoscopy for Detecting Bladder Invasion in the Revised FIGO Staging System for Carcinoma of the Uterine Cervix显示文摘 | Daya Nand Sharma Sanjay Thulkar Shikha Goyal Nootan Kumar Shukla Sunesh Kumar Goura Kisor Rath Parmod Kumar Julka Gagan Saini Amit Bahl | 2010 | International Journal of Gynecological Cancer2010，，3： | 1 |
| 2 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 3 | TIPS Can Be Lifesaving in Acute Liver Failure Associated with Portal Vein and Inferior Vena Cava Thrombosis in a Case of Budd Chiari Syndrome Due to Protein S Deficiency显示文摘 | Ashish Verma Gagan Sharma Suyash Mohan Vivek A. Saraswat Sanjay S. Baijal | 2008 | CardioVascular and Interventional Radiology2008，，2： | 1 |
| 4 | TNF-α-mediated cardiomyocyte apoptosis involves caspase-12 and calpain显示文摘 | Gagan Bajaj Rajendra K. Sharma | 2006 | Biochemical and Biophysical Research Communications2006，，4： | 1 |
| 5 | Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells显示文摘Aim:The development of chemotherapy resistance is the major obstacle in the treatment of advanced prostate cancer(PCa).Extracellular vesicles(EVs)secretion plays a significant role among different mechanisms contributing to chemoresistance.Hence,inhibition of EVs release may increase the efficacy of chemotherapeutic drugs against PCa.Methods:Paclitaxel(PTX)resistant PCa cells(PC3-R and DU145-R)were treated with GW4869,a known exosome biogenesis inhibitor.EVs were isolated from the conditioned media by ExoQuick-based precipitation method and characterized for concentration and size distribution by nanoparticle tracking analysis.The effect of GW4869 treatment on the survival and growth of PCa cells was assessed by MTT,and colony formation assays in vitro,and ectopic PC3-R xenografts in male athymic nude mice in vivo.The effect of other EV biogenesis inhibitors,imipramine and dimethyl amiloride(DMA),treatment was also analyzed on the survival of PC3-R cells.Results:GW4869(10-20μM)treatment of PTX resistant PCa cells significantly reduced the release of small EVs(50-100 nm size range)while increasing the release of larger EVs(>150 nm in size),and inhibited their clonogenicity.Moreover,GW4869(5-20μM)treatment(24-72h)significantly inhibited the survival of PC3-R cells in a dose-dependent manner.We observed a similar growth inhibition with both imipramine(5-20μg/mL)and DMA(5-20μg/mL)treatment in PC3-R cells.Furthermore,GW4869 treatment(IP)in mice bearing PC3-R xenografts significantly reduced the tumor weight(65%reduction,P=0.017)compared to the vehicle-treated control mice without causing any noticeable toxicity.Conclusion:Inhibiting the release of EVs could sensitize the resistant PCa cells to chemotherapy. | Ashish Kumar Pawan Kumar Mitu Sharma Susy Kim Sangeeta Singh Steven J.Kridel Gagan Deep | 2022 | Cancer Drug Resistance2022，5，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员